邓蕊　 刘晓峰

[摘要] 目的 分析卵巢癌術前新辅助化疗疗效及对肿瘤标志物的影响。 方法 选取2016年2月至2017年2月锦州医科大学中国人民解放军967医院妇产科收诊的卵巢癌患者87例，将其中41例在卵巢癌手术前接受新辅助化疗的患者归为观察组，接受常规的术后化疗的46例患者归为对照组，进行回顾性分析。比较两组患者治疗前后肿瘤标志物水平及治疗1、2、3年生存率变化。 结果 治疗前，两组患者CEA、CA19-9、CA125、血清HE4水平比较，差异无统计学意义（P>0.05）。治疗后，两组患者4项肿瘤标志物水平均低于治疗前，且观察组低于对照组，差异有统计学意义（P<0.05）。观察组和对照组患者术后1年生存率分别为85.37%、84.78%，两组比较差异无统计学意义（P>0.05），观察组和对照组术后2年、3年生存率分别为73.17%、56.52%和63.41%、41.30%，观察组高于对照组（P<0.05）。 结论 新辅助化疗能有效提升卵巢癌患者的化疗效果，改善患者血清肿瘤标志物水平，提高术后生存率，具有极高的临床推广价值。

[关键词] 卵巢癌;新辅助化疗;肿瘤标志物;生存率

[中图分类号] R737.31          [文献标识码] A          [文章编号] 1673-9701（2021）06-0013-04

Efficacy of preoperative neoadjuvant chemotherapy for ovarian cancer and its influence on tumor markers

DENG Rui1   LIU Xiaofeng2

1.Graduate Training Base of the 967th Hospital of Chinese People′s Liberation Army， Jinzhou Medical University， Dalian   116000， China; 2.Department of Obstetrics and Gynecology， the 967th Hospital of Chinese People′s Liberation Army， Jinzhou Medical University， Dalian   116000， China

[Abstract] Objective To analyze the efficacy of preoperative neoadjuvant chemotherapy for ovarian cancer and its influence on tumor markers. Methods A total of 87 patients with ovarian cancer in the Department of Obstetrics and Gynecology of 967 Hospital， Jinzhou Medical University from February 2016 to February 2017 were selected. Among them， 41 patients who received neoadjuvant chemotherapy before ovarian cancer surgery were classified as the observation group， and 46 patients who received conventional postoperative chemotherapy were classified as the control group. A retrospective analysis was conducted. The levels of tumor markers were compared before and after treatment and the changes in 1-year， 2-year， and 3-year survival rates after treatment were compared between the two groups. Results Before treatment， there was no significant difference in CEA， CA19-9， CA125 and serum HE4 levels between the two groups（P>0.05）. After treatment， the four tumor markers of the two groups were lower than before treatment， and the observation group was lower than the control group， the difference was statistically significant（P<0.05）. The 1-year survival rates of the observation group and the control group were 85.37% and 84.78%， respectively. There was no significant difference between the two groups（P>0.05）. The 2-year and 3-year survival rates of the observation group and the control group were 73.17%， 56.52% and 63.41%， 41.30% respectively. The observation group was higher than the control group（P<0.05）. Conclusion Neoadjuvant chemotherapy can effectively improve the chemotherapy effect of patients with ovarian cancer， improve the level of serum tumor markers of patients， and improve the survival rate after surgery. It has an extremely high clinical promotion value.

[Key words] Ovarian cancer; Neoadjuvant chemotherapy; Tumor markers; Survival rate

卵巢癌在诸多恶性肿瘤中发生率和致死率均位于前列，且由于卵巢解剖位置位于盆腔深处，早期又缺乏特异性，患者通过自身察觉和常规检测发现的概率较低，因此在确诊时患者多已为卵巢癌Ⅱ、Ⅲ期。相关研究结果显示[1]，卵巢癌患者确诊后生存率通常不超过37%，由于晚期卵巢癌患者丧失了最佳的治疗时机和根治机会，因此多接受长期化疗治疗。卵巢癌新辅助化疗是指在对患者实施局部治疗，或在其手术或放疗前所做的全身化疗，目的是以此来缩小肿块、杀灭转移肿瘤细胞和微小病灶，从而达成延长患者生命的目的[2-3]。本文分析了卵巢癌术前新辅助化疗的疗效及对肿瘤标志物的影响，现报道如下。